WASHINGTON, DC — The intensity of itch experienced by patients on hemodialysis with uremic pruritus can be eased with 12 weeks of treatment with difelikefalin (Korsuva, Cara Therapeutics), results ... Uremic pruritus is a debilitating symptom frequently encountered in individuals with chronic kidney disease (CKD), particularly those receiving haemodialysis. This condition, characterised by ...
A trial supports the use of the calcineurin-inhibitor tacrolimus as a targeted treatment for uremic pruritus and introduces IL-13 inhibition as a viable mechanism to address cytokine-mediated itch. In a phase 3 trial, difelikefalin, a kappa opioid receptor agonist, significant decreased itching and improved itching-related quality of life among dialysis patients suffering from pruritus. BioWorld: Investors 'Cara' bout phase II uremic pruritus data, light up shares Business Insider: Cara Therapeutics Partner Maruishi Submits Difelikefalin NDA In Japan For Pruritus In Hemodialysis Cara Therapeutics Partner Maruishi Submits Difelikefalin NDA In Japan For Pruritus In Hemodialysis Renal & Urology News: KOR Agonists, GABA Analogs May Relieve Uremic Pruritus
